- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was biddin…Endpoints · 2d ago↗ source
- STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027Science Corporation announced the European launch of its retinal implant for patients with age-related macular degeneration.STAT · 2d ago↗ source
- Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugRoyalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.